Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its preliminary financial results for the first quarter of 2026. During the reporting period, the company achieved operating revenue of 2.390 billion yuan, a decrease of 9.17% compared to the same period last year. This reduction was primarily due to the completion of the 100% equity transfer of its former subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., which was excluded from the consolidated financial statements starting March, leading to a corresponding decrease in revenue scale.
Excluding pharmaceutical distribution business, the company's operating revenue was 1.934 billion yuan, representing an increase of 8.38% year-on-year. This growth was mainly attributed to sustained sales growth in pharmaceutical preparation products.
The net profit attributable to shareholders of the listed company for the reporting period was 356 million yuan, marking a significant increase of 83.13% compared to the same period last year. This substantial growth was primarily driven by the one-time gain from the external transfer of the 100% equity stake in Zhejiang Pharmaceutical Industry Co., Ltd., which correspondingly increased non-recurring gains and losses.
Furthermore, the company benefited from increased sales of pharmaceutical preparations and the continuous advancement of lean production and process optimization initiatives, which achieved cost reductions and efficiency improvements in manufacturing. These factors collectively contributed to a favorable growth in the company's net profit after excluding non-recurring items.
Comments